CQN-PHENOM
8.10.2021 04:02:09 CEST | Business Wire | Press release
Fourth paragraph, first sentence of release dated October 6, 2021, should read: As the vice president and general manager for Phenom in Central Europe, Gerstner will be responsible for strengthening existing and new customer relationships in Central Europe, including Germany, Austria, Switzerland, France and BENELUX (instead of in Germany, Austria and Switzerland).
The updated release reads:
PHENOM HIRES SENIOR LEADERS TO OVERSEE RAPID GROWTH IN EUROPE
Thomas Gerstner and Andy Joeres bring decades of experience scaling SaaS enterprises in EMEA
Phenom , the global leader in Talent Experience Management (TXM), today announced the hiring of two executives to drive the company’s surging global growth. Thomas Gerstner will lead Phenom’s business in Central Europe, and Andy Joeres will oversee initiatives in the United Kingdom and Ireland, Northern Europe, Middle East and Africa. The positions were created to continue building momentum in EMEA, where there has been an exploding demand for talent experience, AI and automation from HR teams.
Following numerous acquisitions and the addition of many enterprise customers in EMEA, Phenom’s headcount in Europe has quickly exceeded 100 employees. With operations in the United Kingdom, Ireland, Germany, Netherlands, France, Italy, Spain, Sweden, and Switzerland, Phenom expects to continue aggressively recruiting into 2022 across customer success, sales, account management, marketing, engineering, product and more.
“The need for AI-powered talent experiences is universal, and the interest in Phenom’s platform originating from EMEA is increasing every day,” said Mahe Bayireddi, co-founder and CEO of Phenom. “We’re thrilled that Andy and Thomas are joining our team. They carry proven track records of success meeting ambitious business objectives in many different markets around the world, and we expect their leadership will inspire our talented overseas team to bring amazing talent experiences to global enterprises.”
As the vice president and general manager for Phenom in Central Europe, Gerstner will be responsible for strengthening existing and new customer relationships in Central Europe, including Germany, Austria, Switzerland, France and BENELUX. In his last role, he was the EMEA president of Pathlock — defining, implementing, and executing growth strategy across all channels. For 14 years, Gerstner also held various senior executive roles at SAP, including senior vice president for the SuccessFactors business in the Middle and Eastern European region and managing director in Asia.
“Phenom is already turning heads in Central Europe, and it’s incredible to now be part of this special journey,” said Gerstner. “Organisations that have invested in AI-powered talent experiences are miles ahead of their competitors. Already in Central Europe, Phenom’s sophisticated platform is making a huge difference, helping organizations transform the way they acquire, develop and retain talent.”
Joeres will serve as Phenom’s vice president of sales for EMEA, where he will focus on bringing new business to the company. Joeres has managed the launch of hyper-growth initiatives for companies like Celonis and Snow, where he spearheaded triple-digit, year-over-year growth and exponentially scaled personnel from small teams to large units with deep impact across the enterprise.
“My passion has always been designing go-to-market strategies and then executing them for companies that have a clear, profound vision,” said Joeres. “HR teams are realizing that intelligent experiences are the present and future of hiring and retaining the best talent — and the Phenom TXM platform is the solution. AI and automation are now requirements for scaling those experiences. I look forward to championing Phenom’s platform to help organisations reduce cost and time to hire, while increasing employee retention.”
About Phenom
Phenom is a global HR technology company with a purpose to help a billion people find the right job. With an expertise in building AI-powered, scalable solutions, Phenom Talent Experience Management (TXM) personalizes and automates the talent journey for candidates, recruiters, employees and management with its Career Site, Chatbot, CRM, CMS, SMS and Email Campaigns, University Recruiting, Internal Mobility, Career Pathing, Diversity & Inclusion, Talent Marketplace, Gigs, Referrals, Hiring Manager and Analytics. As a result, employers improve their talent acquisition and talent management efforts by helping candidates and employees find the right job, recruiters identify and engage the right talent, and management optimizes HR strategy, process and spend. Phenom was ranked among the fastest-growing technology companies in the 2020 Deloitte Technology Fast 500, and won a regional 2020 Timmy Award for launching and optimizing HelpOneBillion.com.
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com . Connect with Phenom on LinkedIn , Twitter , Facebook , YouTube and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005383/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom